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BACKGROUND & AIMS:
Exposure to biologic and immunosuppressant agents during breastfeeding is controversial, and there are limited data on safety. We investigated whether biologics are detectable in breast milk from women receiving treatment for inflammatory bowel diseases (IBDs) and whether breastfeeding while receiving treatment is associated with infections or developmental delays. METHODS: We performed a multicenter prospective study of women with IBD and their infants, collecting breast milk samples (n ¼ 72) from patients receiving biologic therapy from October 2013 to November 2015. Drug concentrations were measured in all breast milk samples at several time points within 48 hours of collection and within 168 hours for some samples. Child development was assessed using the Ages and Stages Questionnaire 3, completed by 824 women with IBD (treated or untreated) during pregnancy (620 breastfed, and 204 did not). Data on children's health and development were obtained from mothers and pediatricians, along with information on mothers' medication exposure, IBD history, activity, pregnancy, and postpartum complications. We used chi-squared method or Fisher exact test to determine associations between categorical values and compared differences in continuous outcomes between groups using analysis of variance models. The primary outcome was drug concentration of biologic agents in breast milk (from 72 women) at 1, 12, 24, and 48 hours after dosing and also at 72, 96, 120, and 168 hours for available samples. Secondary outcomes were a range of infant infections and Ages and Stages Questionnaire 3-defined developmental delays among all breastfed infants. RESULTS: We detected infliximab in breast milk samples from 19 of 29 treated women (maximum, 0.74 mg/mL), adalimumab in 2 of 21 treated women (maximum, 0.71 mg/mL), certolizumab in 3 of 13 treated women (maximum, 0.29 mg/mL), natalizumab in 1 of 2 treated women (maximum, 0.46 mg/mL), and ustekinumab in 4 of 6 treated women (maximum, 1.57 mg/mL); we did not detect golimumab in breast milk from the 1 woman receiving this drug. Rates of infection and developmental milestones at 12 months were similar in breastfed vs non-breastfed infants: any infection, 39% vs 39% in control individuals (P > .99) and milestone score, 87 vs 86 in control individuals (P ¼ .9992). Rates of infection and developmental milestones did not differ among infants whose mothers received treatment with biologics, immunomodulators, or combination therapy compared with unexposed infants (whose mothers received treatment with mesalamines or steroids or no medication). CONCLUSIONS: In a study of women receiving treatment for IBD and their infants, we detected low concentrations of infliximab, adalimumab, certolizumab, natalizumab, and ustekinumab in breast milk samples. We found breastfed infants of mothers on biologics, immunomodulators, or combination therapies to have similar risks of infection and rates of milestone achievement compared with non-breastfed infants or infants unexposed to these drugs. Maternal use of biologic therapy appears compatible with breastfeeding. Clinicaltrials.gov no.: NCT00904878.
A vailable data suggest that the use of biologic (monoclonal antibody) therapy during pregnancy does not lead to an increased rate of adverse pregnancy outcomes in women with inflammatory bowel disease (IBD) or their infants. [1] [2] [3] Given the harmful effect of active disease on pregnancy outcomes and the risk of flare with discontinuation of therapy, women are counseled to continue most IBD therapy throughout pregnancy. 4, 5 The biologic medications used to treat IBD currently include infliximab (IFX), adalimumab (ADA), certolizumab pegol (CZP), golimumab (GOL), vedolizumab (VED), natalizumab (NAT), and ustekinumab (UST). IFX, ADA, GOL, VED, and UST are IgG1 monoclonal antibodies and can actively cross the placenta and be detectable in the infant at birth.
6-10 CZP does not have a fragment crystallizable (Fc) portion; therefore, placental transfer is passive and minimal. 9 The American Academy of Pediatrics recommends that women breastfeed for at least 6 months after birth. 11 However, existing data regarding the safety and transfer of biologic agents via breast milk is limited to case reports and small case series. [12] [13] [14] [15] [16] The aim of this study was to determine whether biologic agents are detectable in breast milk and to what degree and to assess whether breastfeeding while taking biologic agents affects rate of infections and achievement of developmental milestones of children born to women with IBD. Mothers who were enrolled in the PIANO registry completed standard comprehensive questionnaires at intake, during each trimester, at birth, and at months 4, 9, and 12 after birth. Data included maternal demographics, age at IBD diagnosis, disease duration and location, disease activity, specific IBD medications used at conception and in each trimester, and complications during pregnancy and postpartum. History of breastfeeding was obtained when the child was 12 months of age, when mothers were asked whether they had breastfed; the duration of breastfeeding; reasons for never breastfeeding or for stopping; and additional details of IBD medications taken, stopped, or avoided during breastfeeding. The breastfeeding questionnaire was introduced to the cohort beginning in 2010.
Materials and Methods
For childhood illnesses, mothers and the child's pediatrician provided information about whether the infant was hospitalized, indication for hospitalization, and diagnosis of infection. Serious infections, defined as pneumonia, sepsis, abscess, bladder infection, cellulitis, meningitis, and those requiring hospitalization, were separated from minor infections, including otitis media and upper respiratory tract infections. Outcomes of infants of mothers exposed to a biologic agent were compared with those of infants of mothers exposed to an immunomodulator (azathioprine/6 mercaptopurine), combination therapy (immunomodulator þ biologic agent), and unexposed mothers (on mesalamine, steroids, or no medication). Mothers measured and reported infant developmental milestones using the Ages and Stages Questionnaire, third edition (ASQ3), a parent-completed developmental screening tool that assesses communication, gross motor, fine motor, problemsolving, and personal adaptive skills at specific ages from 2-60 months. Normative data have been collected from more than 2000 children from diverse ethnic and socioeconomic backgrounds. Suspected development delay is defined as an ASQ3 score 2 or more standard deviations below national means. 17 To characterize presence of monoclonal antibodies in breast milk, all actively breastfeeding women enrolled in the PIANO registry from October 2013 to November 2015 who were taking a biologic medication were asked to provide breast milk samples (0.5-2.0 mL/sample). Samples were collected 1, 12, 24, and 48 hours after drug administration, at various time points after birth. In December 2014, the protocol was amended to allow collection of additional samples at 72, 96, 120, and 168 hours after drug dosing.
The study was approved by the institutional review boards at all participating sites, and all women provided written informed consent. The study was funded by a Senior Research Award (Grant ID A127549) from the Crohn's and Colitis Foundation. All authors had access to the study data and reviewed and approved the final manuscript.
Outcome Measures
The primary outcome was the drug concentration and/or detection of the biologic agent in breast milk at 1, 12, 24, and 48 hours after dosing and also at 72, 96, 120, and 168 hours, when available. Secondary outcomes were a range of infant infections and ASQ3-defined developmental delays among all breastfed infants.
WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT
Biologic medications are commonly used to treat pregnant women with inflammatory bowel disease. Data regarding the safety of breastfeeding while on these medications and transfer of biologics in breast milk is limited.
NEW FINDINGS
Biologic medications are detected in breast milk at very low levels. Breastfed infants of mothers on biologic medications have similar rates of milestone achievement and risk of infection as breastfed infants of mothers not on biologic medications and non-breastfed infants.
LIMITATIONS
Several of the drugs studied had a much smaller sample size. Breast milk samples were only obtained out to 48 hours from drug dosing for most mothers, and to 168 hours for a small group.
IMPACT
This study suggests that biologic medications are compatible with breastfeeding, and there is no increased risk of infection or negative impact on infants exposed to low levels of biologic medications transferred through breast milk.
Determination of Drug Concentrations in Breast Milk
Drug concentrations in breast milk were measured by a previously described homogenous mobility shift assay for drug concentrations in serum. 18 Briefly, 8 standards were generated by a 1:2 linear dilution using normal human breast milk starting at 10 mg/mL. Three positive controls were generated by spiking 2, 1, and 0.5 mg/mL of drug into normal human breast milk. Twelve microliters of either standard, control, or patient sample were added to individual wells of a 96-well, low-protein-binding, round-bottom plate. Normal human breast milk was added without labeled tumor necrosis factor-a (TNF-a) as background subtraction or with labeled TNF-a as a negative control. Appropriate amounts of labeled TNF-a were added, and final volume was brought up to 300 mL with 1 Â phosphate buffered saline/0.1 Â bovine serum albumin. The samples were then filtered using a 0.2-mm Millipore filter (Billerica, MA), and 100 mL was injected onto the high performance liquid chromatography. The TNF-a/drug complexes and the free TNF-a were then resolved on a Phenomenex (Torrance, CA) Yarra size-exclusion column. A standard curve was generated by plotting the proportion-shifted area [bound TNF-a/ (bound TNF-a þ unbound TNF-a)] vs drug concentration. Patient samples and controls were then interpolated from this curve to determine the drug concentration. A similar process was used for non-TNF biologics. All samples were analyzed by Prometheus Labs, Inc (San Diego, CA) at no cost.
Statistical Analysis
We examined univariate frequencies and distributional parameters of laboratory test results, outcomes, and characteristics of the study population to identify outliers or implausible values and to permit checking model assumptions. To estimate the associations between maternal IBD drug exposures and developmental milestones and rates of infections, we calculated chi-square or Fisher exact P values for associations between categorical values and estimated F statistics using analysis of variance models to determine differences in continuous outcomes between various exposure groups.
Results
Patient Characteristics
A total of 824 women completed the breastfeeding status questionnaire (Table 1) . Overall, 620 (75%) women breastfed, and 204 (25%) did not. The average age of those who breastfed was 31.2 years, and the average duration of disease was 8.4 years. There was no difference in age (P ¼ .8404) or duration of disease (P ¼ .3766) between those who breastfed and those who did not. Of the women who breastfed, 58% had Crohn's disease (CD), 40% had ulcerative colitis (UC), and 2% had inflammatory bowel disease unclassified (IBDU). Of those who completed the breastfeeding survey, 72 women submitted breast milk samples. Women who provided breast milk samples were of similar age (31.8 years) and had similar disease duration (9.1 years) as women who did not. Women with lower gestational disease activity were more likely to provide breast milk samples, with women in the lowest quartile of disease activity more than 3 times as likely to provide a sample than those in highest quartile (P ¼ .0361). Of those women who submitted breast milk samples, 68% had CD, 28.6% had UC, and 3.6% had IBDU. Among the 824 women with information on breastfeeding, there was no significant difference in breastfeeding status between those with CD, UC, and IBDU. The likelihood of breastfeeding decreased with increasing disease activity ( Table 1) . Among women who breastfed, women with moderate (10.3%) or severe (0.2%) disease activity were less likely to breastfeed than women with no (72.3%) or mild (17.2%) disease activity (P ¼ .0018). Unexposed women (85%) were significantly more likely to breastfeed compared with women on immunomodulators (65%), biologics (75%), and combination therapy (67%) (P < .0001) ( Table 2) Among women who did not breastfeed, the most common reasons were concerns about exposing their baby to IBD medications (40%, 48/121) and personal preference (24%, 19/121) ( Figure 1 ). Ten percent of patients said their doctor recommended that they not breastfeed. Sixteen of 26 patients who reported "other" for not breastfeeding provided specific reasons, which were primarily related to difficulty with milk production or latching and work schedules. Reasons for not breastfeeding were similar regardless of type of drug exposure. Few women (13%, 80/626) reported stopping an IBD medication during or after pregnancy to breastfeed. In addition, 12% (75/634) of women chose not to take an additional IBD medication to breastfeed. At 1 year, 28% (172/623) of women were still breastfeeding, and 27% (171/623) had stopped because of personal preference or the baby's age. Duration of breastfeeding did not differ among drug exposure groups, but women with higher disease activity breastfed for a shorter duration (P ¼ .04).
Breast Milk Concentrations
Seventy-two women submitted breast milk samples: 29 IFX, 21 ADA, 13 CZP, 1 GOL, 6 UST, and 2 NAT ( 
Infection, Growth, and Development
Among the 824 women with breastfeeding data, per the ASQ3, there was no increased risk of developmental delay or lack of milestone achievement at 12 months in infants who were breastfed compared with not breastfed (Table 4) , and ASQ3 scores of breastfed infants did not differ by maternal medical therapy (Table 5 ). There was no difference in rates (20) 125 (20) 40 (20) NICU, neonatal intensive care unit; OM, otitis media; SD, standard deviation.
of infection among infants who were breastfed and those who were not (Table 4) . Breastfed infants exposed to immunomodulators, biologics, or combination therapy had similar milestone achievement and were also not more likely to have an infection in the first 12 months of life compared with unexposed infants or infants who were not breastfed (Table 5 ). This was true for all infections and also when excluding otitis media, the most common infection. Of note, breastfed infants were numerically more likely (39% vs 36%) to attend daycare and/or have a sibling in daycare (62% vs 48%).
Discussion
To our knowledge, this is the largest prospective observational study evaluating biologic breast milk transfer from women with IBD to their infants and includes data for nearly all of the biologic medications currently used to treat IBD. In this study, IFX, ADA, CZP, UST, and NAT were all detected in breast milk samples, but at very low concentrations. Concomitant immunomodulator use did not affect drug detection in breast milk. Among the cohort of 824 infants, breastfeeding while receiving biologic therapy did not adversely affect the rate of infection or achievement of developmental milestones compared with not breastfeeding.
Recommendations have historically been for women receiving anti-TNF-a or biologic therapy to avoid breastfeeding. However, breastfeeding should be low risk, because IgA is the predominant immunoglobulin found in breast milk, and the biologic agents evaluated here are all in the IgG subclass. 19, 20 Therefore, secretion and transfer in breast milk should be minimal.
Current data evaluating the concentrations of the anti-TNF-a drugs IFX, ADA, and CZP in breast milk are limited to case reports. 8, 9, [12] [13] [14] [15] [16] These have shown trivial transfer of IFX, [13] [14] [15] [16] ADA, 12,14 CZP, 21 and UST, 22 similar to our study. Monoclonal antibody therapy may be absorbed to some small degree from the gut. An infant who had no intrauterine infliximab exposure and was exposed to the drug only through breast milk after the mother initiated IFX in the postpartum period had a serum concentration of 1.7 mg/mL 5 days after the mother's second IFX infusion. 14 The mechanism of absorption is not clear, but it has been postulated to involve the FcRn, which is expressed in a variety of neonatal tissues and the intestinal cells of adults and fetuses. 23, 24 We considered whether it would be helpful to understand the serum pharmacokinetics of these biologic medications to predict degree and timing of detectable breast milk concentrations by looking at the drug half-life and C max (time to maximum serum concentration). Half-life and C max for each agent are listed in Table 6 . 22, [25] [26] [27] [28] [29] For IFX, 8 women submitted samples our to 168 hours, of whom 5 had detectable concentrations beyond 48 hours as well as between 1 and 48 hours after infusion. Therefore, it is unlikely that we missed any samples with detectable IFX concentrations beyond 48 hours among the women who did not have detectable concentrations between 1 and 48 hours and extended data. For ADA, it is possible that the drug would be detected with sampling out to 7 days when peak serum concentration occurs. However, in our small sample, peak breast milk concentration was seen 12-24 hours after dosing, and no drug was detected in 7 women who provided samples out to 168 hours. Similarly, 2 women receiving CZP who provided samples out to 168 hours did not have detectable breast milk concentrations at any time point. In our small sample size for UST, peak breast milk concentrations were seen 12-72 hours after injection, and the drug was detected beyond 48 hours in 75%. Finally, for NAT, neither of the 2 women in our study submitted samples beyond 48 hours. However, as was the case in a prior case report, the drug could be detected with extended sampling. 30 Finally, the overall rate of breastfeeding in the PIANO registry was 75%, which is slightly lower than the average rate of 81.1% of infants who start to breastfeed in the United States. 31 Our study shows that significantly fewer women taking immunomodulators and biologics breastfeed compared with women not taking these medications. The most common reasons for not breastfeeding were concern for drug transfer to the infant and personal preference. Physician recommendation was also influential. Better data and provider and patient education should help increase rates of breastfeeding in this population.
This study has several strengths and limitations. It is the largest long-term, prospective observational study of nursing mothers and their infants. Breast milk concentrations were measured at multiple time points and infants were followed up to at least 1 year. In addition, breast milk concentrations were analyzed using assays that calibrated the standard curve with breast milk. All drug concentrations were analyzed with this assay methodology. One limitation is that the sample sizes were small for GOL, NAT, and UST. Next, lack of extended breast milk samples collected may be important. Only 22 of 72 (14%) women submitted breast milk samples between 48 hours and 168 hours after drug dosing. Whereas infusion-based medications have a C max immediately after infusion, injection-based drugs have a longer time to C max . Although this was not seen in our small sample of injection-based drugs, it is possible that the drugs could be detected with extended sampling. Next, breastfeeding in general has been associated with lower rates of infection, including otitis media. 32, 33 We looked at all infections, including otitis media, and infections excluding otitis media to be able to capture more serious infections. We also queried mothers regarding daycare exposure. Although our sample size with breast milk samples is small, the overall cohort of 824 women with breastfeeding data is well characterized and supports the low risk associated with breastfeeding while receiving biologic therapy.
Finally, infant cord drug concentrations at birth and serum concentrations after birth as a result of placental transfer may have a greater impact on infection and development outcomes than breast milk transfer, and time of breast milk sample after birth may also be important. In this study, breast milk samples were mostly obtained within 3 months of birth, when some concentration of placental transfer would be present. We did not have serum samples from all infants who also had breast milk concentrations, so we were unable to perform this analysis. However, among 14 infants who did have serum concentrations at birth, there was no correlation between infant serum concentration, age at breast milk sample, or days between blood and breast milk sample. There was also no correlation between age at breast milk sample and detection in breast milk. Furthermore, prior studies have shown no difference in infection outcomes in infants exposed in utero to biologic monotherapy based on concentration of the drug in infants at birth. 34, 35 Therefore, although lack of placental transfer data is a limitation of our study, it is not likely to have an impact on infection outcomes.
In conclusion, lactation is compatible with the use of maternal biologic therapy based on minimal transfer rates in breast milk and no association with infant infections and achievement of developmental milestones. Continued long-term prospective data collection is necessary, and more data are needed to characterize the pharmacokinetics of the newer biologic agents GOL, UST, and VED. 
